查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016189

血漿蛋白治療市場：依產品、適應症、給藥途徑及最終用戶分類－2026-2032年全球市場預測

Plasma Protein Therapeutics Market by Product, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血漿蛋白療法市場價值將達到 303.8 億美元，到 2026 年將成長至 319.7 億美元，到 2032 年將達到 437.8 億美元，複合年成長率為 5.35%。

主要市場統計數據
基準年 2025 303.8億美元
預計年份：2026年 319.7億美元
預測年份 2032 437.8億美元
複合年成長率 (%) 5.35%

全面說明血漿蛋白療法的生物學原理、製造複雜性、臨床作用和策略系統級依賴性。

血漿蛋白製劑是現代臨床醫學的基礎，廣泛應用於止血、免疫學和緊急醫療等挽救生命的領域。本書系統地說明了血漿衍生蛋白和重組蛋白的生物學基礎，描述了關鍵的生產流程，例如供體採集和分離，並闡明了每種治療藥物在現代臨床實踐中的分類。本書重點介紹了這些治療方法如何用於治療急性創傷、先天性出血性疾病、免疫力缺乏和標靶預防，並著重探討了其供應和交付過程中所面臨的臨床緊迫性和操作複雜性。

對正在重塑血漿蛋白療法的生產、分銷和臨床應用的變革性技術、監管和供應鏈變化進行了深入的概述。

血漿蛋白療法的格局正受到一系列趨同且變革性變化的影響，這些變化正在改變其生產、分銷和臨床應用。生產技術的進步正在加速製程最佳化，從而實現更高的產量、更有效率的病毒去活化以及更擴充性的分離方法。同時，重組技術和替代表達平台的成熟，正在傳統血漿衍生產品與生物技術開發的替代產品之間形成新的競爭動態。

詳細分析美國關稅措施的變化如何影響整個血漿療法生態系統供應鏈的經濟、籌資策略和營運應對措施。

美國關稅政策近期的變化為全球血漿療法供應鏈的多個環節帶來了複雜性。進口原料、特殊耗材和某些成品生技藥品的關稅上漲，增加了接收成本，改變了供應商的選擇標準，並促使製造商重新評估其籌資策略和合約條款。當上游投入來自高關稅市場時，這些成本壓力尤其顯著，迫使企業考慮近岸外包、策略性庫存累積或重新談判長期供應商契約，以保護利潤率並維持供應的連續性。

從徹底的細分觀點出發，詳細分析產品分類、治療適應症、給藥途徑和醫療保健環境，從而定義供需動態。

細分市場分析揭示了影響臨床實踐和商業策略的、在產品分類、適應症、給藥途徑和最終用戶方面存在的微妙趨勢。在產品類型中，白蛋白在液體管理和急診醫學中仍然至關重要，有低濃度和高濃度製劑可供選擇，以滿足各種臨床場景的需求。凝血因子繼續在治療遺傳性和後天性出血性疾病中發揮作用，其產品半衰期和給藥複雜性各不相同，而凝血酶原複合物濃縮物則具有快速糾正功能。針對特定病原體的免疫球蛋白為肝炎、狂犬病、破傷風和水痘-帶狀皰疹等疾病提供了標靶預防和暴露後治療方案，在控制疫情爆發方面具有重要的臨床意義。免疫球蛋白療法在免疫調節中繼續發揮核心作用，可透過靜脈注射或皮下注射給藥，給藥途徑的選擇會影響患者體驗、輸注環境和給藥間隔。

詳細的區域評估突顯了美洲、歐洲、中東、非洲和亞太地區在基礎設施、監管環境和產能舉措方面的差異。

區域趨勢持續影響全球血漿蛋白療法的產能、供應和監管合規性。美洲地區擁有完善的捐贈者網路、一體化的分離基礎設施和物流系統，能夠支援大規模的採集和分發，這為其提供了有利條件。雖然這種區域優勢保障了供應的可靠性，但也面臨成本上升和監管審查的壓力，因此需要持續投資於品質提升。

對企業策略進行清晰的概述，重點在於對生產能力、技術差異化、合作夥伴關係和綜合服務模式的投資，這些都塑造了企業的競爭地位。

主要企業和區域廠商之間的競爭動態反映了其策略重點，例如擴大產能、產品差異化和垂直整合。老牌廠商持續投資於先進的分餾設施、病原體去除技術和拓展分銷網路，以確保供應可靠性和合規性。同時，新興生物技術公司和合約研發公司正在開發重組生產平台和特殊製劑，旨在滿足尚未滿足的市場需求或提供給藥優勢。

一系列切實可行且影響深遠的建議，旨在幫助領導者加強供應韌性、擴大獲取途徑，並加速整個血漿療法價值鏈的創新。

產業領導者應採取積極主動的策略，以應對供應韌性、臨床應用和長期創新等問題。首先，透過區域夥伴關係和擴大血漿採集網路來實現採購多元化，可以減輕貿易摩擦和關稅成本波動的影響。投資於模組化和可擴展的生產能力，以及先進的病毒去活化和純化技術，將提高營運柔軟性並加強品質保證。

採用透明的混合方法研究途徑，結合與關鍵相關人員的訪談、二次技術檢驗和情境分析，有助於獲得可操作的策略見解。

本執行摘要的研究採用了混合方法，旨在兼顧營運實際情況和策略觀點。主要定性研究包括對臨床專家、生產經理、採購負責人和監管專家進行結構化訪談，以揭示實際挑戰和新興實踐。隨後，將這些見解與二手文獻、行業技術指南和公開的監管文件進行交叉比對，以檢驗趨勢並識別技術轉折點。

整合技術、供應和政策因素，明確維持血漿蛋白療法准入和競爭的策略重點。

總之，血漿蛋白製劑仍然是現代醫療保健的重要組成部分，但該領域目前正經歷重大變革時期。生產和製劑技術的進步、以患者為中心的給藥模式的演變，以及對供應鏈韌性的日益關注，都在重新定義製造商和醫療保健系統的運作方式。不斷變化的貿易政策和持續更新的法規進一步加劇了商業環境的複雜性，要求企業採取策略性應對措施，優先考慮區域生產能力、透明度以及與支付方和監管機構的合作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血漿蛋白產品市場：依產品分類

  • 白蛋白
    • 5％
    • 25％
  • 凝血因子
    • 因子IX
    • 因子 VIII
    • 凝血酶原複合物濃縮液
  • 高免疫球蛋白
    • B型肝炎
    • 狂犬病
    • 破傷風
    • 水痘和帶狀皰疹
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白

第9章：血漿蛋白產品市場：依適應症分類

  • 心血管系統
  • 神經系統
  • 原發性免疫力缺乏
  • 次發性免疫力缺乏
  • 創傷

第10章：血漿蛋白產品市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第11章 血漿蛋白產品市場：依最終用戶分類

  • 診所
  • 醫院

第12章 血漿蛋白產品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血漿蛋白產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血漿蛋白產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血漿蛋白產品市場

第16章：中國血漿蛋白產品市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ADMA Biologics, Inc.
  • Baxter International, Inc.
  • Bio Products Laboratory Ltd
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • GC Pharma
  • Grifols, SA
  • Hualan Biological Engineering Inc.
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB SA
  • Octapharma AG
  • Sanquin Plasma Products BV
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-030EE4851670

The Plasma Protein Therapeutics Market was valued at USD 30.38 billion in 2025 and is projected to grow to USD 31.97 billion in 2026, with a CAGR of 5.35%, reaching USD 43.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.38 billion
Estimated Year [2026] USD 31.97 billion
Forecast Year [2032] USD 43.78 billion
CAGR (%) 5.35%

A comprehensive foundational introduction that explains the biological basis, production complexity, clinical roles, and strategic system-level dependencies of plasma protein therapeutics

Plasma protein therapeutics constitute a cornerstone of modern clinical care, spanning life-saving applications in hemostasis, immunology, and critical care. This introduction frames the biological rationale for plasma-derived and recombinant proteins, explains core production pathways such as donor collection and fractionation, and situates therapeutic classes within contemporary clinical practice. It highlights how these therapies address acute trauma, congenital bleeding disorders, immune deficiencies, and targeted prophylaxis, emphasizing both the clinical urgency and the operational complexity that underpin supply and delivery.

Moreover, the introduction outlines systemic dependencies that shape the sector, including donor availability, cold-chain logistics, and rigorous pathogen safety protocols. It presents the interplay between innovation and regulation, noting advances in recombinant production and purification alongside evolving guidance to safeguard patients. Finally, it clarifies the strategic stakes for stakeholders: clinicians require predictable supply and consistent clinical performance, manufacturers must balance capacity and quality controls, and health systems need resilient procurement pathways. Together, these elements create the context for deeper analysis of technological shifts, trade dynamics, and segmentation-level implications provided in the subsequent sections.

An insightful synthesis of transformative technological, regulatory, and supply chain shifts reshaping production, distribution, and clinical adoption of plasma protein therapies

The landscape for plasma protein therapeutics has been reshaped by a set of convergent, transformative shifts that alter production, distribution, and clinical use. Advances in manufacturing technologies have accelerated process optimization, enabling higher yields, improved viral inactivation, and more scalable fractionation approaches. At the same time, recombinant techniques and alternative expression platforms are maturing, creating new competitive dynamics between traditional plasma-derived products and biologically engineered alternatives.

Supply chain resilience has moved to the forefront, driven by pandemic-era disruptions and heightened geopolitical trade friction. Stakeholders now prioritize diversified sourcing strategies, regional capacity investments, and digital traceability to ensure continuity. Clinically, there is a clear pivot toward therapies that enable outpatient administration and improved patient convenience, prompting formulation adaptations and delivery innovations. Regulatory frameworks are evolving in parallel, with greater emphasis on pharmacovigilance, batch traceability, and cross-border harmonization of safety standards. Taken together, these shifts demand integrated strategies across R&D, manufacturing, distribution, and stakeholder engagement to translate scientific advances into reliable patient access and sustainable commercial models.

A detailed analysis of how evolving United States tariff measures are altering supply chain economics, sourcing strategies, and operational responses across the plasma therapeutics ecosystem

Recent tariff policy changes implemented by the United States have introduced a layer of complexity that affects multiple nodes of the global plasma therapeutics supply chain. Tariffs on imported raw materials, specialized consumables, and certain finished biologics increase landed costs and alter supplier selection criteria, prompting manufacturers to re-evaluate sourcing strategies and contractual terms. These cost pressures are disproportionately felt where upstream inputs originate from markets subject to elevated duties, leading firms to consider nearshoring, strategic inventory buildup, or renegotiation of long-term supplier agreements to protect margins and maintain supply continuity.

In response, some manufacturers are accelerating investments in domestic fractionation capacity and expanding partnerships with regional plasma collection networks to reduce exposure to cross-border tariff volatility. Payers and procurement teams are also reassessing tender frameworks and reimbursement pathways to reflect adjusted acquisition costs. Meanwhile, regulatory compliance and customs administration become more complex, requiring enhanced documentation, tariff classification expertise, and operational adjustments to avoid delays. Ultimately, the cumulative effect incentivizes a rebalancing of global flows, greater emphasis on supply chain transparency, and pragmatic trade-offs between cost, speed, and redundancy to protect patient access while preserving commercial viability.

A thorough segmentation-driven perspective detailing product classes, therapeutic indications, administration routes, and care settings that define demand and delivery dynamics

Segmentation analysis reveals nuanced trends across product classes, indications, routes of administration, and end users that shape clinical practice and commercial strategy. Within product categories, albumin remains critical for volume management and critical care, with formulations spanning lower and higher concentration presentations suited to different clinical scenarios. Coagulation factors continue to serve hereditary and acquired bleeding disorders, including products for factors that vary in half-life and administration complexity, while prothrombin complex concentrates offer rapid correction capabilities. Hyperimmune globulins tailored to specific pathogens provide targeted prophylaxis and post-exposure options for diseases such as hepatitis, rabies, tetanus, and varicella zoster, and they retain clinical relevance in outbreak responses. Immunoglobulin therapies maintain a central role in immune modulation, delivered either intravenously or via subcutaneous routes, with route choice influencing patient experience, infusion setting, and dosing cadence.

Regarding indications, cardiovascular support, neurological immune modulation, primary and secondary immunodeficiencies, and trauma-related resuscitation each drive distinct demand patterns and clinical pathways. Routes of administration influence healthcare delivery models: traditional intravenous delivery in institutional settings competes with growing adoption of subcutaneous alternatives that enable home administration and reduce hospital resource utilization. Finally, end users such as clinics and hospitals demonstrate different procurement behaviors and capacity constraints; hospitals typically manage acute inpatient demand and complex storage logistics, whereas clinics increasingly support chronic therapy administration and decentralized care. Together, these segmentation layers inform product development priorities, channel strategies, and clinical support models needed to optimize access and adherence.

A nuanced regional assessment highlighting the differing infrastructure, regulatory landscapes, and capacity initiatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to influence capacity, access, and regulatory navigation across the global continuum of plasma protein therapeutics. The Americas landscape benefits from a well-established donor network, integrated fractionation infrastructure, and logistical systems that support high-volume collection and distribution. This regional capability underpins supply reliability but also faces pressure from cost inflation and regulatory scrutiny that demand continuous quality investments.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement frameworks shape product availability and adoption rhythms. Some markets feature advanced clinical pathways and robust hospital systems that drive complex therapy utilization, while others require targeted access programs and capacity building to expand availability. Policymakers in the region are increasingly focused on traceability and safety harmonization, which affects cross-border supply and compliance costs.

Asia-Pacific presents a dynamic mix of rapid demand growth, expanding local manufacturing investments, and variable plasma collection capacity. Increasing healthcare access, rising clinician awareness of plasma therapies, and strategic investments in regional fractionation capabilities are fostering capacity expansion. However, supply resilience remains uneven across markets, requiring manufacturers to tailor distribution models, invest in local partnerships, and deploy education programs to align clinical practice with best-in-class safety and efficacy standards.

An incisive overview of company strategies emphasizing capacity investment, technological differentiation, alliances, and integrated service models that shape competitive positioning

Competitive dynamics among leading firms and regional players reflect strategic priorities that include capacity expansion, product differentiation, and vertical integration. Established manufacturers continue to invest in state-of-the-art fractionation facilities, pathogen reduction technologies, and extended distribution networks to maintain supply reliability and regulatory compliance. At the same time, emerging biotechnology companies and contract developers are advancing recombinant production platforms and specialty formulations intended to address unmet clinical needs or offer administration advantages.

Strategic partnerships, licensing agreements, and targeted acquisitions have become common pathways for incumbents to secure product pipelines, access novel technologies, or strengthen regional footprints. Quality systems, lot-to-lot consistency, and traceability are competitive differentiators that inform procurement decisions by hospitals and clinics. Additionally, companies are expanding patient support services, educating clinicians on route selection and home-based therapy protocols, and collaborating with payers to align reimbursement with clinical outcomes. These combined moves illustrate a marketplace that values integrated solutions, predictable supply, and demonstrable clinical benefit as core commercial imperatives.

A set of pragmatic, high-impact recommendations for leaders to strengthen supply resilience, broaden access, and accelerate innovation across the plasma therapeutics value chain

Industry leaders should adopt a proactive agenda that addresses supply resilience, clinical accessibility, and long-term innovation. First, diversifying sourcing through regional partnerships and expanding plasma collection networks can reduce exposure to trade friction and tariff-driven cost volatility. Investing in modular and scalable manufacturing capacity, as well as advanced viral inactivation and purification technologies, will improve operational flexibility and strengthen quality assurance.

Second, prioritize product and delivery innovations that support outpatient and home-based administration, particularly by expanding subcutaneous formulations and patient training initiatives. These shifts reduce hospital burden and enhance adherence while opening new commercial channels. Third, engage early and constructively with regulators and payers to align evidence generation with reimbursement expectations and to streamline cross-border compliance pathways. Fourth, implement robust supply chain transparency measures and scenario planning to manage disruptions, including strategic inventory positioning and contractual clauses that mitigate risk. Finally, embed digital tools across the value chain to optimize donor recruitment, cold-chain monitoring, and pharmacovigilance, thereby enhancing traceability and operational efficiency. Together, these actions will balance short-term resilience with long-term competitiveness and patient-centered outcomes.

A transparent mixed-methods research approach combining primary stakeholder interviews, secondary technical validation, and scenario analysis to support actionable strategic insights

The research underpinning this executive summary employed a mixed-methods approach designed to capture both operational realities and strategic perspectives. Primary qualitative engagement included structured interviews with clinical specialists, manufacturing leaders, procurement officers, and regulatory experts to surface frontline challenges and emergent practices. These insights were triangulated with secondary literature, industry technical guidance, and publicly available regulatory documents to validate trends and identify technological inflection points.

Analytical processes applied thematic synthesis for qualitative data, operational mapping for supply chain assessment, and scenario analysis to explore the implications of trade policy shifts. Careful attention was given to data provenance and source triangulation to limit bias and increase confidence in directional findings. Limitations include the variable speed of regulatory changes and the confidentiality constraints around proprietary manufacturing metrics, both of which can limit granularity. Nevertheless, the methodology emphasizes transparency, reproducibility, and relevance for decision-makers seeking actionable intelligence grounded in clinical, operational, and regulatory realities.

A decisive conclusion synthesizing technological, supply, and policy drivers to clarify strategic priorities for sustaining access and competitiveness in plasma protein therapies

In conclusion, plasma protein therapeutics remain indispensable to modern healthcare, yet the sector is navigating a period of significant transformation. Technological advances in production and formulation, evolving administration paradigms that favor patient-centric delivery, and heightened attention to supply chain resilience collectively redefine how manufacturers and health systems must operate. Trade policy shifts and regulatory evolution further complicate the operating environment, prompting strategic responses that prioritize regional capacity, transparency, and collaborative engagement with payers and regulators.

Moving forward, organizations that integrate investments in manufacturing robustness, innovative delivery formats, and targeted clinical evidence generation will be best positioned to sustain reliable patient access while preserving commercial viability. The ability to anticipate disruptions, adapt procurement and distribution strategies, and align cross-functional initiatives around quality and traceability will determine who succeeds in this complex landscape. Stakeholders should therefore view this juncture as an opportunity to modernize operational models, strengthen partnerships across the value chain, and deliver measurable clinical benefit in an increasingly patient-centric environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Protein Therapeutics Market, by Product

  • 8.1. Albumin
    • 8.1.1. Five Percent
    • 8.1.2. Twenty Five Percent
  • 8.2. Coagulation Factor
    • 8.2.1. Factor IX
    • 8.2.2. Factor VIII
    • 8.2.3. Prothrombin Complex Concentrate
  • 8.3. Hyperimmune Globulin
    • 8.3.1. Hepatitis B
    • 8.3.2. Rabies
    • 8.3.3. Tetanus
    • 8.3.4. Varicella Zoster
  • 8.4. Immunoglobulin
    • 8.4.1. Intravenous Immunoglobulin
    • 8.4.2. Subcutaneous Immunoglobulin

9. Plasma Protein Therapeutics Market, by Indication

  • 9.1. Cardiovascular
  • 9.2. Neurological
  • 9.3. Primary Immunodeficiency
  • 9.4. Secondary Immunodeficiency
  • 9.5. Trauma

10. Plasma Protein Therapeutics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Plasma Protein Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals

12. Plasma Protein Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Plasma Protein Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Plasma Protein Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Plasma Protein Therapeutics Market

16. China Plasma Protein Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ADMA Biologics, Inc.
  • 17.6. Baxter International, Inc.
  • 17.7. Bio Products Laboratory Ltd
  • 17.8. Biotest AG
  • 17.9. China Biologic Products Holdings, Inc.
  • 17.10. CSL Behring
  • 17.11. GC Pharma
  • 17.12. Grifols, S.A.
  • 17.13. Hualan Biological Engineering Inc.
  • 17.14. Kamada Ltd.
  • 17.15. Kedrion Biopharma
  • 17.16. LFB S.A.
  • 17.17. Octapharma AG
  • 17.18. Sanquin Plasma Products B.V.
  • 17.19. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 174. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 210. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 211. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 212. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 213. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)